NF-κB2 mutation targets TRAF1 to induce lymphomagenesis

Blood

Volumn 110, Issue 2, 2007, Pages 743-751

  Zhang, Baochun ^a   Wang, Zhe ^a   Li, Tai ^a   Tsitsikov, Erdyni N ^b   Ding, Han Fei ^a  

^a UNIVERSITY OF TOLEDO   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC TRANSCRIPTION; HOMEOSTASIS; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; LYMPHOMA; MALE; MITOGENESIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; TRANSGENIC MOUSE; ANIMAL; CELL NUCLEUS; CELL SURVIVAL; FLOW CYTOMETRY; GENETICS; HUMAN; LYMPHOCYTE ACTIVATION; PATHOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; FLOW CYTOMETRY; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; LYMPHOMA; MICE; MICE, TRANSGENIC; MUTAGENESIS, SITE-DIRECTED; NF-KAPPA B P52 SUBUNIT; POLYMERASE CHAIN REACTION; TNF RECEPTOR-ASSOCIATED FACTOR 2; TRANSCRIPTION, GENETIC;

EID: 34547138171     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-11-058446     Document Type: Article

References (49)

1. Gilmore TD. Introduction to NF-κB: players, pathways, perspectives. Oncogene. 2006;25:6680-6684.
2. Basseres DS, Baldwin AS. Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression. Oncogene. 2006;25:6817-6830.
3. Karin M, Greten FR. NF-κB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5:749-759.
4. Courtois G, Gilmore TD. Mutations in the NF-κB signaling pathway: implications for human disease. Oncogene. 2006;25:6831-6843.
5. Neri A, Chang CC, Lombardi L, et al. B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-κB p50. Cell. 1991;67:1075-1087.
6. Fracchiolla NS, Lombardi L, Salina M, et al. Structural alterations of the NF-κB transcription factor lyt-10 in lymphoid malignancies. Oncogene. 1993;8:2839-2845.
7. Migliazza A, Lombardi L, Rocchi M, et al. Heterogeneous chromosomal aberrations generate 3′ truncations of the NFKB2/lyt-10 gene in lymphoid malignancies. Blood. 1994;84:3850-3860.
8. Thakur S, Lin HC, Tseng WT, et al. Rearrangement and altered expression of the NFKB-2 gene in human cutaneous T-lymphoma cells. Oncogene. 1994;9:2335-2344.
9. Zhang J, Chang CC, Lombardi L, Dalla-Favera R. Rearranged NFKB2 gene in the HUT78 T-lymphoma cell line codes for a constitutively nuclear factor lacking transcriptional repressor functions. Oncogene. 1994;9:1931-1937.
10. Chang CC, Zhang J, Lombardi L, Neri A, Dalla-Favera R. Rearranged NFKB-2 genes in lymphoid neoplasms code for constitutively active nuclear transactivators. Mol Cell Biol. 1995;15:5180-5187.
11. Ciana P, Neri A, Cappellini C, et al. Constitutive expression of lymphoma-associated NFKB-2/Lyt-10 proteins is tumorigenic in murine fibroblasts. Oncogene. 1997;14:1805-1810.
12. Pircher H, Mak TW, Lang R, et al. T cell tolerance to Mlsa encoded antigens in T cell receptor V beta 8.1 chain transgenic mice. EMBO J. 1989;8:719-727.
13. Zhang Y, Schlossman SF, Edwards RA, Ou C-N, Gu J, Wu MX. Impaired apoptosis, extended duration of immune responses, and a lupus-like autoimmune disease in IEX-1-transgenic mice. Proc Natl Acad Sci U S A. 2002;99:878-883.
14. Tsitsikov EN, Laouini D, Dunn IF, et al. TRAF1 is a negative regulator of TNF signaling: enhanced TNF signaling in TRAF1-deficient mice. Immunity. 2001;15:647-657.
15. Wang Y, Cui H, Schroering A, et al. NF-κB2 p100 is a pro-apoptotic protein with anti-oncogenic function. Nat Cell Biol. 2002;4:888-893.
16. Finco TS, Beg AA, Baldwin AS Jr. Inducible phosphorylation of IκB alpha is not sufficient for its dissociation from NF-κB and is inhibited by protease inhibitors. Proc Natl Acad Sci U S A. 1994;91:11884-11888.
17. Adams JM, Harris AW, Pinkert CA, et al. The c-myc oncogene driven by immunoglobulin enhancers induced lymphoid malignancy in transgenic mice. Nature. 1985;318:533-538.
18. Hedrick SM, Cohen DI, Nielsen EA, Davis MM. Isolation of cDNA clones encoding T cell-specific membrane-associated proteins. Nature. 1984;308:149-153.
19. Hao H, Qi H, Ratnam M. Modulation of the folate receptor type beta gene by coordinate actions of retinoic acid receptors at activator Sp1/ets and repressor AP-1 sites. Blood. 2003;101:4551-4560.
20. Schwenzer R, Siemienski K, Liptay S, et al. The human tumor necrosis factor (TNF) receptor-associated factor 1 gene (TRAF1) is up-regulated by cytokines of the TNF ligand family and modulates TNF-induced activation of NF-κB and c-Jun N-terminal kinase. J Biol Chem. 1999;274:19368-19374.
21. Cui H, Schroering A, Ding HF. p53 mediates DNA damaging drug-induced apoptosis through a caspase-9-dependent pathway in SH-SY5Y neuroblastoma cells. Mol Cancer Ther. 2002;1:679-686.
22. Krebs DL, Yang Y, Dang M, Haussmann J, Gold MR. Rapid and efficient retrovirus-mediated gene transfer into B cell lines. Methods Cell Sci. 1999;21:57-68.
23. Morse HC III, Anver MR, Fredrickson TN, et al. Bethesda proposals for classification of lymphoid neoplasms in mice. Blood. 2002;100:246-258.
24. Rathmell JC, Thompson CB. Pathways of apoptosis in lymphocyte development, homeostasis, and disease. Cell. 2002;109(suppl):S97-S107.
25. Chu Z-L, McKinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci U S A. 1997;94:10057-10062.
26. Wang C-Y, Mayo MV, Korneluk RG, Goeddel DV, Baldwin AS. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and cIAP1 and cIAP2 to suppress caspase-8 activation. Science. 1998;281:1680-1683.
27. Tang G, Minemoto Y, Dibling B, et al. Inhibition of JNK activation through NF-κB target genes. Nature. 2001;414:313-317.
28. Chen C, Edelstein LC, Gelinas C. The Rel/NF-kB family directly activates expression of the apoptosis inhibitor Bcl-XL. Mol Cell Biol. 2000;20:2687-2695.
29. Epinat JC, Kazandjian D, Harkness DD, et al. Mutant envelope residues confer a transactivation function onto N-terminal sequences of the v-Rel oncoprotein. Oncogene. 2000;19:599-607.
30. Benhamou LE, Cazenave PA, Sarthou P. Anti-immunoglobulins induce death by apoptosis in WEHI-231 B lymphoma cells. Eur J Immunol. 1990;20:1405-1407.
31. Hasbold J, Klaus GG. Anti-immunoglobulin antibodies induce apoptosis in immature B cell lymphomas. Eur J Immunol. 1990;20:1685-1690.
32. Caamano JH, Rizzo CA, Durham SK, et al. Nuclear factor (NF)-κB2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responses. J Exp Med. 1998;187:185-196.
33. Franzoso G, Carlson L, Poljak L, et al. Mice deficient in nuclear factor (NF)-κB/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. J Exp Med. 1998;187:147-159.
34. Schiemann B, Gommerman JL, Vora K, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science. 2001;293:2111-2114.
35. Claudio E, Brown K, Park S, Wang H, Siebenlist U. BAFF-induced NEMO-independent processing of NF-kB2 in maturing B cells. Nat Immunol. 2002;3:958-965.
36. Kayagaki N, Yan M, Seshasayee D, et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kB2. Immunity. 2002;17:515-524.
37. Solan NJ, Miyoshi H, Carmona EM, Bren GD, Paya CV. RelB cellular regulation and transcriptional activity are regulated by p100. J Biol Chem. 2002;277:1405-1418.
38. Coope HJ, Atkinson PG, Huhse B, et al. CD40 regulates the processing of NF-κB2 p100 to p52. EMBO J. 2002;21:5375-5385.
39. Arch RH, Gedrich RW, Thompson CB. Tumor necrosis factor receptor-associated factors (TRAFs) - a family of adapter proteins that regulates life and death. Genes Dev. 1998;12:2821-2830.
40. Bradley JR, Pober JS. Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene. 2001;20:6482-6491.
41. Durkop H, Foss HD, Demel G, Klotzbach H, Hahn C, Stein H. Tumor necrosis factor receptor-associated factor 1 is overexpressed in Reed-Sternberg cells of Hodgkin's disease and Epstein-Barr virus-transformed lymphoid cells. Blood. 1999;93:617-623.
42. Izban KF, Ergin M, Martinez RL, Alkan S. Expression of the tumor necrosis factor receptor-associated factors (TRAFs) 1 and 2 is a characteristic feature of Hodgkin and Reed-Sternberg cells. Mod Pathol. 2000;13:1324-1331.
43. Zapata JM, Krajewska M, Krajewski S, et al. TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. J Immunol. 2000;165:5084-5096.
44. Murray PG, Flavell JR, Baumforth KR, et al. Expression of the tumor necrosis factor receptor-associated factors 1 and 2 in Hodgkin's disease. J Pathol. 2001;194:158-164.
45. Munzert G, Kirchner D, Stobbe H, et al. Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis. Blood. 2002;100:3749-3756.
46. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102:3871-3879.
47. Cahir McFarland ED, Izumi KM, Mosialos G. Epstein-Barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-kappaB. Oncogene. 1999;18:6959-6964.
48. Lee SY, Reichlin A, Santana A, Sokol KA, Nussenzweig MC, Choi Y. TRAF2 is essential for JNK but not NF-κB activation and regulates lymphocyte proliferation and survival. Immunity. 1997;7:703-713.
49. Zapata JM, Krajewska M, Morse HC III, Choi Y, Reed JC. TNF receptor-associated factor (TRAF) domain and Bcl-2 cooperate to induce small B cell lymphoma/chronic lymphocytic leukemia in transgenic mice. Proc Natl Acad Sci U S A. 2004;101:16600-16605.